Hologic, Inc. (LON:0J5Q)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 12.47B |
| Revenue (ttm) | 3.06B |
| Net Income (ttm) | 421.84M |
| Shares Out | n/a |
| EPS (ttm) | 1.86 |
| PE Ratio | 29.56 |
| Forward PE | 16.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101 |
| Average Volume | 943 |
| Open | 75.03 |
| Previous Close | 75.10 |
| Day's Range | 74.98 - 75.07 |
| 52-Week Range | 51.86 - 75.39 |
| Beta | 0.70 |
| RSI | 65.82 |
| Earnings Date | Jan 30, 2026 |
About Hologic
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginos... [Read more]
Financial Performance
In 2025, Hologic's revenue was $4.10 billion, an increase of 1.74% compared to the previous year's $4.03 billion. Earnings were $565.70 million, a decrease of -28.35%.
Financial numbers in USD Financial StatementsNews
HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases
Hologic shares dip as the company unveils new study data showing its Genius AI mammography flags 32% of previously missed breast cancer cases.
Why Hologic (HOLX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Hologic's AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--Hologic's AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exam...
What Is Driving Hologic's Strength in the US Diagnostics Market?
HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.
HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026?
Hologic shares rise 16% in six months, with divisional strength clinical data and a go-private deal shaping the short-term outlook.
How Is The Market Feeling About Hologic Inc?
Hologic Inc's (NYSE: HOLX) short interest as a percent of float has risen 14.43% since its last report. According to exchange reported data, there are now 3.89 million shares sold short , which is 2....
Hologic's BCI Test Shows Growing Impact in Endocrine Therapy Decisions
HOLX's BCI test gains traction as new SABCS studies are set to highlight its growing role in guiding extended endocrine therapy decisions.
PSP, Oaktree Among Direct Lenders Buying $2 Billion Hologic Debt3
Canada’s PSP Investments, Oaktree Capital Management, Franklin Templeton and other private lenders snapped up about $2 billion of subordinated debt that banks had committed to after financing Blacksto...
New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test.
HOLX vs. DGX: Which Healthcare Diagnostics Stock Is the Better Bet?
DGX's strong YTD gains and momentum in advanced diagnostics and acquisitions highlight why it may stand out in the competitive testing market against HOLX.
New Clinical Evidence Bolsters Hologic's Breast Cancer Technologies
HOLX is set to present new real-world data at RSNA 2025, showing how its AI-driven breast imaging tools boost workflow without sacrificing detection.
New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA.
Here Are Friday’s Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More
Pre-Market Stock Futures:The futures are trading higher as we get ready to close out a volatility-filled week that saw a massive roller coaster ride on Thursday after NVIDIA Corp. (NASDAQ: NVDA) earni...
Hologic's GYN Surgical Delivers a Standout Quarter: What's Behind It?
HOLX's GYN Surgical segment posts its strongest fiscal 2025 growth as MyoSure, Fluent and Gynesonics fuel a standout quarter.
Decoding Hologic Inc (HOLX): A Strategic SWOT Insight
Decoding Hologic Inc (HOLX): A Strategic SWOT Insight
Should You Continue to Hold Hologic Stock Post Q4 Earnings?
HOLX's solid Q4 growth and a pending $18.3B buyout sharpen its focus as the company prepares to end its publicly traded chapter.
P/E Ratio Insights for Hologic
Looking into the current session, Hologic Inc. (NASDAQ: HOLX) shares are trading at $74.35, after a 0.12% increase. Moreover, over the past month, the stock increased by 6.23% , but in the past year,...
Hologic Expands European Reach of Genius Digital Diagnostics System
HOLX gains expanded CE marking for its Genius Digital Diagnostics System, enabling imaging of both cell and tissue specimens on one platform.
Here's Why Hologic (HOLX) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #cemark--Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking.
HOLX Maintains Equal-Weight Rating as Morgan Stanley Raises Price Target | HOLX Stock News
HOLX Maintains Equal-Weight Rating as Morgan Stanley Raises Price Target | HOLX Stock News
Hologic, Inc. (HOLX) Announces Approval of Revised RSU Award Agreement
Hologic, Inc. (HOLX) Announces Approval of Revised RSU Award Agreement
HOLX Stock Up on Q4 Earnings & Revenue Beat, Operating Margin Expands
Hologic posts solid Q4 gains with earnings and revenue beat, margin expansion, and a buyout deal by Blackstone and TPG.
Hologic, Inc. 2025 Q4 - Results - Earnings Call Presentation
2025-11-04. The following slide deck was published by Hologic, Inc.
Hologic Inc Q4 Profit Rises
(RTTNews) - Hologic Inc (HOLX) released earnings for its fourth quarter that Increases, from the same period last year